Gauruv Bose
Associate Scientist, Neuroscience
Ottawa Hospital Research Institute
Assistant Professor, Neurology, Department of Medicine
University of Ottawa
Attending Neurologist, Department of Medicine
The Ottawa Hospital
Research Interests
1. Multiple Sclerosis and Neuro-immunology
2. Predictive modelling of outcomes and treatment decisions
3. Machine learning / artificial intelligence approaches to assessing “Big Data”-sets
Brief Biography
Dr. Gauruv Bose is full-time academic neurologist at the Ottawa Hospital, Department of Medicine, Division of Neurology, and assistant professor at the University of Ottawa, Faculty of Medicine. He completed a Clinical Research Fellow in Multiple Sclerosis and Neuroimmunology at Mass General Brigham & Harvard Medical School, and is now primarily seeing patients with Multiple Sclerosis and related neuro-immunological disorders.
His research consists of investigating large real-world datasets of patients with Multiple Sclerosis (MS) to develop predictive models using machine learning techniques, as well as building on this research forefront by investigating the added value of implementing novel imaging and serum biomarkers into these predictive models.
Selected Publications
1. Bose G, Healy BC, Barro C, Glanz BI, Lokhande HA, Polgar-Turcsanyi M, Guttmann CR, Bakshi R, Weiner HL, Chitnis T. Younger age at multiple sclerosis onset is associated with worse outcomes at age 50. J Neurol Neurosurg Psychiatry. 2022 Aug 11:jnnp-2022-329353. doi: 10.1136/jnnp-2022-329353. Epub ahead of print. PMID: 35953266.
2. Molazadeh N, Bose G, Lotan I, Levy M. Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review. Mult Scler J Exp Transl Clin. 2022 Oct 20;8(4):20552173221128170. doi: 10.1177/20552173221128170. PMID: 36311694; PMCID: PMC9597055.
3. Holroyd KB, Healy BC, Conway S, Houtchens M, Bakshi R, Bhattacharyya S, Bose G, Galetta K, Kaplan T, Severson C, Singhal T, Stazzone L, Zurawski J, Polgar-Turcsanyi M, Saxena S, Paul A, Glanz BI, Weiner HL, Chitnis T. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes. Mult Scler Relat Disord. 2022 Nov;67:104079. doi: 10.1016/j.msard.2022.104079. Epub 2022 Jul 28. PMID: 35952457; PMCID: PMC9330583.
4. Bose G, Healy BC, Lokhande HA, Sotiropoulos MG, Polgar-Turcsanyi M, Anderson M, Glanz BI, Guttman CRG, Bakshi R, Weiner HL, Chitnis T. Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis. Ann Neurol. 2022 Jul;92(1):87-96. doi: 10.1002/ana.26370. Epub 2022 May 4. PMID: 35429009.
5. Bose G, Rush C, Atkins HL, Freedman MS. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult Scler Relat Disord. 2021 Jul;52:102945. doi: 10.1016/j.msard.2021.102945. Epub 2021 Apr 11. PMID: 33901969.
Diseases, conditions and populations of interest
Research and clinical approaches
